Analysts Have Conflicting Sentiments on These Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Pacira Pharmaceuticals (PCRX) and Eliem Therapeutics (ELYM)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Arrowhead Pharmaceuticals (ARWR – Research Report), Pacira Pharmaceuticals (PCRX – Research Report) and Eliem Therapeutics (ELYM – Research Report).

Arrowhead Pharmaceuticals (ARWR)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Arrowhead Pharmaceuticals today and set a price target of $90.00. The company’s shares closed last Thursday at $33.16.

According to TipRanks.com, Trucchio has 0 stars on 0-5 stars ranking scale with an average return of -15.3% and a 31.1% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Milestone Pharmaceuticals, and Precision BioSciences.

Currently, the analyst consensus on Arrowhead Pharmaceuticals is a Strong Buy with an average price target of $58.44, which is a 77.2% upside from current levels. In a report issued on February 6, Robert W. Baird also maintained a Buy rating on the stock with a $58.00 price target.

See today’s best-performing stocks on TipRanks >>

Pacira Pharmaceuticals (PCRX)

H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Pacira Pharmaceuticals today and set a price target of $69.00. The company’s shares closed last Thursday at $40.09, close to its 52-week low of $35.35.

According to TipRanks.com, Livnat is a 1-star analyst with an average return of -1.3% and a 41.2% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Verrica Pharmaceuticals, and Satsuma Pharmaceuticals.

Currently, the analyst consensus on Pacira Pharmaceuticals is a Strong Buy with an average price target of $61.38, a 48.8% upside from current levels. In a report issued on January 31, Wedbush also maintained a Buy rating on the stock with a $60.00 price target.

Eliem Therapeutics (ELYM)

H.C. Wainwright analyst Douglas Tsao downgraded Eliem Therapeutics to Hold today. The company’s shares closed last Thursday at $3.34, close to its 52-week low of $2.36.

According to TipRanks.com, Tsao is a 5-star analyst with an average return of 15.5% and a 46.2% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Praxis Precision Medicines, and Crinetics Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Eliem Therapeutics with a $4.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ARWR:

• Arrowhead price target lowered to $55 from $59 at B. Riley
• 3 Stocks to Buy Today, 2/8/2023, According to Top Analysts
• Arrowhead price target lowered to $77 from $83 at RBC Capital
• Arrowhead price target lowered to $58 from $60 at Baird
• Arrowhead price target lowered to $52 from $55 at Piper Sandler